A Phase 2 interventional study of Lanraplenib and Filgotinib in Cutaneous Lupus Erythematosus, sponsored by Gilead Sciences. Completed at 16 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-09.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 17th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2017, is one of 15 in phase 2, and was the 16th registered.
67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.
Browse Lupus Erythematosus, Cutaneous studies →10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:
Beeline Medicines Corporation · Sites in United States
Ages 16+
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Victoria Werth · Sites in United States
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 7
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 32 across 57 interventional studies indexed under Lupus Erythematosus, Cutaneous.
Median enrollment 46 across the 34 interventional studies, 77 across the 5 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 39 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 4 studies filed under Lupus Erythematosus, Cutaneous — fewer than ten, so there is no comparison to draw.
3 of the studies in Lupus Erythematosus, Cutaneous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07260877Ventus Therapeutics U.S., Inc.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | 2026-12 |
| NCT06625671DualityBio Inc.A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | 2027-06-30 |
| NCT06661213Northwestern UniversityTapinarof for Cutaneous Lupus Erythematosus | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).
Key Inclusion Criteria:
Must have a diagnosis of CLE, either chronic (e.g., discoid) or subacute CLE per investigator evaluation, with the following:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lanraplenib + filgotinib placebo for 48 weeks
Drug: Lanraplenib · Drug: Filgotinib placebo
Filgotinib + lanraplenib placebo for 48 weeks
Drug: Filgotinib · Drug: Lanraplenib placebo
Filgotinib placebo + lanraplenib placebo for 12 weeks
Drug: Lanraplenib placebo · Drug: Filgotinib placebo
After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
Drug: Lanraplenib · Drug: Filgotinib placebo
After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
Drug: Filgotinib · Drug: Lanraplenib placebo
30 mg tablets administered orally once daily with or without food
Also known as: GS-9876
200 mg tablets administered orally once daily with or without food
Also known as: GS-6034
Tablets administered orally once daily with or without food
Tablets administered orally once daily with or without food
Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
Time frame: Baseline; Week 12
Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
Time frame: Baseline; Week 12
Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.
Time frame: Baseline; Week 12
Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
Time frame: Baseline; Week 24
Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.
Time frame: Baseline; Week 24
Participants were enrolled at study sites in the United States and Canada. The first participant was screened on 24 May 2017. The last study visit occurred on 18 December 2019.
| Milestone | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Placebo to Lanraplenib 30 mg | Placebo to Filgotinib 200 mg |
|---|---|---|---|---|---|
| Started | 19 | 18 | 10 | 0 | 0 |
| Completed | 14 | 14 | 8 | 0 | 0 |
| Not completed | 5 | 4 | 2 | 0 | 0 |
| Withdrew: Adverse event | 4 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 | 1 | 0 | 0 |
| Milestone | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Placebo to Lanraplenib 30 mg | Placebo to Filgotinib 200 mg |
|---|---|---|---|---|---|
| Started | 14 | 14 | 0 | 4 | 4 |
| Completed | 12 | 11 | 0 | 3 | 3 |
| Not completed | 2 | 3 | 0 | 1 | 1 |
| Withdrew: Withdrew consent | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
| score on a scale | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo |
|---|---|---|---|
| Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 | -4.5 ± 1.91 | -8.7 ± 1.85 | -5.5 ± 2.56 |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
| Percentage of participants | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo |
|---|---|---|---|
| Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | 47.4 (24.4 to 71.1) | 64.7 (38.3 to 85.8) | 44.4 (13.7 to 78.8) |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.
| Percentage of participants | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo |
|---|---|---|---|
| Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline | 84.2 (60.4 to 96.6) | 94.1 (71.3 to 99.9) | 88.9 (51.8 to 99.7) |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.
| Percentage of participants | Lanraplenib 30 mg | Filgotinib 200 mg |
|---|---|---|
| Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | 50.0 (23.0 to 77.0) | 83.3 (51.6 to 97.9) |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.
| Percentage of participants | Lanraplenib 30 mg | Filgotinib 200 mg |
|---|---|---|
| Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline | 85.7 (57.2 to 98.2) | 100.0 (73.5 to 100.0) |
Collected over First dose date up to Week 48 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lanraplenib 30 mg | 0/19 (0%) | 2/19 (10.5%) | 17/19 (89.5%) |
| Filgotinib 200 mg | 0/17 (0%) | 1/17 (5.9%) | 11/17 (64.7%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Placebo to Lanraplenib 30 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Placebo to Filgotinib 200 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Placebo to Lanraplenib 30 mg | Placebo to Filgotinib 200 mg |
|---|---|---|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/19 | 1/17 | 0/9 | 0/4 | 0/4 |
| Coronary artery occlusionCardiac disorders | 1/19 | 0/17 | 0/9 | 0/4 | 0/4 |
| Drug hypersensitivityImmune system disorders | 1/19 | 0/17 | 0/9 | 0/4 | 0/4 |
| Event | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Placebo to Lanraplenib 30 mg | Placebo to Filgotinib 200 mg |
|---|---|---|---|---|---|
| Dry eyeEye disorders | 0/19 | 1/17 | 0/9 | 1/4 | 0/4 |
| Aphthous ulcerGastrointestinal disorders | 0/19 | 0/17 | 0/9 | 0/4 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 2/19 | 1/17 | 0/9 | 0/4 | 1/4 |
| CystitisInfections and infestations | 0/19 | 0/17 | 0/9 | 0/4 | 1/4 |
| NasopharyngitisInfections and infestations | 1/19 | 0/17 | 0/9 | 1/4 | 0/4 |
| Tooth fractureInjury, poisoning and procedural complications | 0/19 | 0/17 | 0/9 | 1/4 | 0/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/19 | 0/17 | 0/9 | 1/4 | 0/4 |
| HeadacheNervous system disorders | 2/19 | 4/17 | 0/9 | 0/4 | 1/4 |
| Skin lesionSkin and subcutaneous tissue disorders | 0/19 | 0/17 | 0/9 | 1/4 | 0/4 |
| HypertensionVascular disorders | 0/19 | 0/17 | 0/9 | 0/4 | 1/4 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 51 ± 9.0 | 43 ± 11.5 | 46 ± 7.3 | 47 ± 10.1 |
| Sex: Female, Male(Participants) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 19 | 17 | 9 | 45 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 2 | 2 |
| Black | 6 | 8 | 1 | 15 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| White | 12 | 7 | 6 | 25 |
| Other | 0 | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 2 | 9 |
| Not Hispanic or Latino | 16 | 13 | 7 | 36 |
| Region of Enrollment(participants) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| Canada | 4 | 1 | 3 | 8 |
| United States | 15 | 16 | 6 | 37 |
| Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score(score on a scale) | Lanraplenib 30 mg | Filgotinib 200 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 17.1 ± 6.11 | 19.7 ± 14.35 | 14.8 ± 4.79 | 17.6 ± 9.89 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Mar 2019, 21 months.
Results were first posted in Apr 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lanraplenib · GLPG0634
Lupus Erythematosus, Cutaneous →